# PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

> **NCT05007145** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 92 (estimated)

## Conditions studied

- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT05007145
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-15
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2021-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007145, "PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05007145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*